Understanding Pityriasis Alba: A Common, Benign Skin Condition

Pityriasis alba is a very common and harmless skin condition, particularly prevalent among children and adolescents, typically between the ages of 3 and 16. It manifests as patches of lighter-coloured skin, often appearing on the face, upper arms, neck, and upper trunk. It is more common in individuals with darker skin types and is characterised by a prolonged course, with remissions and recurrences. While its appearance can be a source of concern for parents and individuals, it’s important to understand that Pityriasis alba is a benign, self-limiting condition that usually resolves on its own.

What is Pityriasis Alba?

The name Pityriasis alba itself gives insight into the condition; “pityriasis” refers to the fine, flaky scaling that may appear on the skin, and “alba” means white, describing the pale marks it often leaves behind. The condition typically goes through stages. It usually begins as faintly red or pink, dry, and slightly scaly patches, often round or oval in shape. These initial patches gradually lose their redness and scaling, but they leave behind lighter (hypopigmented) areas of skin.

These pale patches become more obvious after sun exposure, as the surrounding skin tans while the affected areas remain light due to reduced melanin production. Some children may experience mild itching, but in most cases, the patches are symptomless. Pityriasis alba is harmless and not contagious, and the patches usually fade on their own over time, though this may take several months to a few years.

What Causes Pityriasis Alba?

The exact cause of Pityriasis alba is not fully understood, but it is widely considered a mild form of atopic dermatitis, a type of eczema. This connection suggests an underlying inflammatory process in the skin. While not contagious, several factors are thought to contribute to its development, including:

• Atopic conditions — individuals with a personal or family history of atopic conditions like eczema, asthma, or allergic rhinitis are more prone to developing Pityriasis alba.

• Sun exposure — while not a direct cause, sun exposure can make the lighter patches more prominent as the surrounding skin darkens.

• Dry skin (Xerosis Cutis) — poor skin hydration, excessive exfoliation, and frequent hot baths may also play a role.

Symptoms of Pityriasis Alba

The hallmark symptom of Pityriasis alba is the presence of light-coloured patches on the skin. These patches typically present with the following characteristics:

• Hypopigmented — the patches are lighter than the surrounding skin due to reduced melanin.

• Shape and Size — they may be round, oval, or irregular in shape, usually ranging from 0.5 to 5 centimeters in diameter.

• Texture — in early stages, patches may appear slightly red and scaly; over time, they become smoother and more noticeably pale.

• Location — most frequently observed on the face (especially the cheeks), as well as the neck, upper arms, and upper trunk.

• Itchiness — generally asymptomatic, though mild itching may occur in some cases.

The contrast between affected and unaffected skin is often more noticeable in individuals with darker skin tones or following sun exposure.

Clinical Variants of Pityriasis Alba

Pityriasis alba presents in three clinical variants: Classic, Extensive, and Pigmenting.

• Classic Pityriasis Alba is the most common form. It typically appears in primary school-aged children as small, round or oval hypopigmented patches on the face, particularly the cheeks. The patches are usually few in number and respond well to basic moisturisers or mild topical corticosteroids.

• Extensive Pityriasis Alba involves a larger surface area and tends to affect adolescents or young adults. The patches may appear not just on the face but also on the neck, shoulders, upper arms, and trunk. This form often follows a longer, more stubborn course and may not respond as quickly to treatment.

• Pigmenting Pityriasis Alba is a less common variant. It may initially appear similar to the classic form but evolves with areas of both lighter and darker pigmentation (hypo- and hyperpigmentation). This variant also tends to have a more prolonged duration and may be more resistant to standard treatment approaches.

Each variant shares the hallmark feature of pigmentary change, but the distribution, age group affected, and treatment response can differ significantly.

How is Pityriasis Alba Diagnosed? 

Pityriasis alba is usually diagnosed based on clinical evaluation. A doctor can typically identify the condition by closely examining the affected skin, especially if the presentation is typical. No laboratory tests are routinely required.

However, if the appearance is atypical or if there is uncertainty about the diagnosis, especially to differentiate it from conditions like tinea versicolor or vitiligo, additional tests may be performed:

• Wood’s Lamp Examination — this involves using ultraviolet light to examine the skin. Some fungal infections fluoresce under the light, helping distinguish them from Pityriasis alba, which does not.

• Potassium Hydroxide (KOH) Test — a scraping of the skin is examined under a microscope after applying KOH to check for fungal elements, particularly if a fungal infection like tinea versicolor is suspected.

• Skin Biopsy — rarely needed, but may be considered in unclear or persistent cases. It involves removing a small sample of skin for microscopic examination.

Most cases do not require these investigations, as the diagnosis can be confidently made based on the clinical features alone.

Treatment and Management of Pityriasis Alba

It is important for both patients and parents to understand that Pityriasis alba is a harmless condition. While the patches may take several months to a few years to fully resolve, the skin usually regains its normal pigmentation over time without the need for specific treatment. There is no permanent "cure" because the condition often clears on its own. However, certain measures can help reduce dryness, ease mild itching, and improve the overall appearance of the affected areas during the healing process.

• Moisturisers (Emollients) — applying moisturisers regularly helps keep the skin hydrated, reduces dryness and flaking, and supports the skin’s natural barrier. This simple step often plays a key role in managing the condition and promoting healthier-looking skin..

• Sun Protection — shielding the affected areas from sun exposure is essential. Applying a broad-spectrum sunscreen with SPF 30 or higher and wearing protective clothing, such as hats and long sleeves, can help prevent sunburn and reduce the visibility of pale patches by minimising the contrast with surrounding tanned skin.

• Mild Topical Corticosteroids — when patches show persistent redness, scaling, or itching, a healthcare provider may suggest using a mild topical steroid, such as hydrocortisone 1%, for a limited duration. This can help calm inflammation and improve the skin’s appearance.

• Topical Calcineurin Inhibitors — non-steroidal creams such as pimecrolimus may be recommended for individuals who are concerned about long-term steroid use or who do not respond well to corticosteroids. These medications help reduce inflammation and itching. They may also influence melanin production, gradually improving the discolouration of the affected areas over time.

• Avoiding Irritants — keeping the skin away from harsh soaps, fragranced products, and other potential irritants can help prevent further dryness and inflammation. Using gentle, fragrance-free cleansers and avoiding overwashing can support the skin’s healing process and reduce the risk of worsening the patches. 

Prognosis for Pityriasis Alba

The long-term outlook for Pityriasis alba is very favorable. The hypopigmented patches are temporary and typically resolve gradually, often disappearing entirely by early adulthood. Although recurrences can occur, especially with dry skin or sun exposure, the condition does not cause scarring or result in any lasting health issues. With appropriate skin care, most individuals experience complete recovery over time.

When to Contact a Medical Professional

Although Pityriasis alba is generally a benign condition, it is advisable to consult a healthcare provider in the following situations:

• You have concerns about changes in your child’s skin.
• The patches are noticeably itchy, uncomfortable, or worsening.
• There are signs of infection, such as pus, increased redness, warmth, or fever.
• The appearance of the patches is causing distress to the child or family.
• You are uncertain about the diagnosis and wish to rule out other skin conditions.

Understanding Pityriasis alba and maintaining consistent skin care can go a long way in managing the condition and supporting overall skin health.

Summary 

Pityriasis alba is a non-contagious eczema-like skin condition most commonly seen in children and adolescents in Singapore. It appears as white, dry patches on a child’s skin, often more visible after sun exposure. While it usually resolves on its own, treatments such as moisturisers, sun protection, and occasional topical medications can help improve its appearance and reduce discomfort. 

Recognising the condition early can prevent unnecessary worry and interventions. If your child has persistent or unclear skin changes, schedule a consultation with APAX Medical & Aesthetics Clinic for a thorough evaluation and guidance on effective management.

Frequently Asked Questions (FAQs) 

References

1. Miazek N, Michalek I, Pawlowska‐Kisiel M, Olszewska M, Rudnicka L. Pityriasis alba—common disease, enigmatic entity: Up‐to‐date review of the literature. Pediatric dermatology. 2015 Nov;32(6):786-91.
2. Fujita WH, McCormick CL, Parneix‐Spake A. An exploratory study to evaluate the efficacy of pimecrolimus cream 1% for the treatment of pityriasis alba. International journal of dermatology. 2007 Jul;46(7):700-5.
3. Rigopoulos D, Gregoriou S, Charissi C, Kontochristopoulos G, Kalogeromitros D, Georgala S. Tacrolimus ointment 0· 1% in pityriasis alba: an open‐label, randomized, placebo‐controlled study. British Journal of Dermatology. 2006 Jul 1;155(1):152-5.